MedTrace Logo

Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms

NCT04379024 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2021-10-29

No results posted yet for this study

Summary

Pilot study to test feasibility of 6 months of Duavee® vs wait-list control in post-menopausal women symptomatic for hot flashes.

Conditions

  • Focus of Study is Healthy Women at Risk for Breast Cancer

Interventions

DRUG

DUAVEE 0.45Mg-20Mg Tablet

One capsule daily for 6 months (+/- 1 month)

Sponsors & Collaborators

  • Breast Cancer Research Foundation

    collaborator OTHER

  • Carol Fabian, MD

    lead OTHER

Principal Investigators

  • Carol J Fabian, MD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-07-30
Completion
2021-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04379024 on ClinicalTrials.gov